주식/증권
📈 긍정적
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
요약
Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.